Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688186 | 0.85 | TP53 (0.47) | CA1CA2TP53TSHR | |
| SCHEMBL23395298 | 0.77 | TPMT (0.52) | TPMTCA1CA2GSK3BTRPV1 | |
| SCHEMBL3760858 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3BPHGDH | |
| SCHEMBL3841301 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3B | |
| SCHEMBL1244094 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3B | |
| SCHEMBL1994288 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3BTRPV1 | |
| SCHEMBL9389844 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3B | |
| SCHEMBL9173480 | 0.77 | SRD5A2 (0.55) | — | |
| SCHEMBL9769554 | 0.77 | RAB9A (0.46) | GSK3BRXRARXRBPTPN1TP53 | |
| SCHEMBL79334 | 0.74 | TPMT (1.00) | TPMTCA1CA2GSK3BRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325573-A1 | X-RAY DEVELOPABLE MOLECULE, EMBOLISM MICROSPHERE AND PREPARATION METHODS THEREFOR | SHANGHAI HUIHE HEALTHCARE TECHNOLOGY CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2023124736-A1 | X-RAY DEVELOPABLE MOLECULE, X-RAY DEVELOPABLE EMBOLIC MICROSPHERE AND PREPARATION METHOD THEREFOR | 上海汇禾医疗科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023124736-A1 | X-RAY DEVELOPABLE MOLECULE, X-RAY DEVELOPABLE EMBOLIC MICROSPHERE AND PREPARATION METHOD THEREFOR | 上海汇禾医疗科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-114262279-B | X-ray developable molecule, embolism microsphere and preparation method thereof | 上海汇禾医疗科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-114262279-A | X-ray developable molecule, embolism microsphere and preparation method thereof | 上海汇禾医疗科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11111348-B2 | Method for treating surface of resin material layer and resin material | MITSUBISHI HEAVY INDUSTRIES, LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| EP-3450488-B1 | METHOD FOR TREATING SURFACE OF RESIN MATERIAL LAYER AND RESIN MATERIAL | MITSUBISHI HEAVY IND LTD (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-20200317876-A1 | METHOD FOR TREATING SURFACE OF RESIN MATERIAL LAYER AND RESIN MATERIAL | MITSUBISHI HEAVY INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-8773745-B2 | Electrochromic material | KYUSHU UNIVERSITY (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20110149367-A1 | ELECTROCHROMIC MATERIAL | KYUSHU UNIVERSITY (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7638637-B2 | Immunomodulators; amino-functional imidazole phosphonates and analogues thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638637-B2 | Immunomodulators; amino-functional imidazole phosphonates and analogues thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | S1PR3, S1PR1, S1PR5 | TPMT 1567/4885CA1 4063/4885CA2 2972/4885 |
| US-20240325573-A1 | X-RAY DEVELOPABLE MOLECULE, EMBOLISM MICROSPHERE AND PREPARATION METHODS THEREFOR | F11, FAR1, FGB | TPMT 3699/4885CA1 1982/4885CA2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.